{"id": "267227", "url": "https://fevir.net/resources/EvidenceVariable/267227", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"], "versionId": "9", "lastUpdated": "2025-12-11T20:35:21.032Z"}, "title": "Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) (NCT03421379)", "author": [{"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}], "citeAs": "Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) (NCT03421379) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 267227. Revised 2025-12-11. Available at: https://fevir.net/resources/EvidenceVariable/267227. Computable resource at: https://fevir.net/resources/EvidenceVariable/267227#json.", "status": "active", "contact": [{"telecom": [{"value": "support@computablepublishing.com", "system": "email"}]}], "contained": [{"id": "variable-definition", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/conceptual-cohort-definition"]}, "membership": "conceptual", "resourceType": "Group", "characteristic": [{"code": {"text": "defined by CodeableConcept"}, "timing": [{"text": "Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration"}], "exclude": false, "valueCodeableConcept": {"text": "Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM)"}}]}], "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/", "publisher": "Computable Publishing LLC", "definition": {"reference": {"type": "Group", "reference": "#variable-definition"}}, "identifier": [{"type": {"text": "FEvIR Object Identifier", "coding": [{"code": "ACSN", "system": "http://terminology.hl7.org/CodeSystem/v2-0203", "display": "Accession ID"}]}, "value": "267227", "system": "https://fevir.net/FOI", "assigner": {"display": "Computable Publishing LLC"}}, {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03421379-secondaryOutcome-0", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}], "description": "PD assessment measured the change from Baseline in maximal blood glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride intramuscular (IM).", "resourceType": "EvidenceVariable", "name": "Pharmacodynamics_PD_Change_From_Baseline_in_Maximal_Blood_Glucose_BGmax_of_Glucagon_Nasal_Powder_and_Glucagon_Hydrochloride_Intramuscular_IM_NCT03421379", "extension": [{"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/evidence-variable-handling-detail", "valueCodeableConcept": {"coding": [{"code": "evidence-variable-handling-not-specified", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Evidence variable handling not specified"}]}}], "handling": "extension"}